Clinical Evaluation of Recombinant Factor VIII Preparation (Kogenate) in Previously Treated Patients with Hemophilia A: Descriptive Meta-Analysis of Post-Marketing Study Data
- 233 Downloads
The safety and efficacy of Kogenate, a recombinant factor VIII (rFVIII) preparation for the treatment of bleeding episodes, were studied in a 123-patient meta-analysis population of previously treated patients (PTPs), including 15 enrolled in the registration Phase III trial (PTP-I group), 93 from the post-marketing special investigation (PTP-II group), and 15 from short-term special investigations in surgery or tooth extraction (SI group). These patients (82 severe, 31 moderate, 9 mild, and 1 unknown), aged 11 months to 72 years, were enrolled in 28 centers in Japan. Blood samples taken at the baseline and at 3, 6, 9, 12, 18, and 24 months after the introduction of Kogenate were evaluated for FVIII inhibitor antibodies, antibodies formed against trace proteins derived from the rFVIII production process, and for general changes in laboratory test results. Mean exposure to Kogenate was 1103 days in PTP-I, 86 days in PTP-II, 27 days in patients in surgery, and 2 days in patients with tooth extraction.
Assessment of FVIII inhibitor activity was conducted in 115 of the 123 patients by means of the Bethesda assay. Twelve patients were found to have a low titer of FVIII inhibitor (0.5–3.0 BU/mL) prior to any administration of Kogenate, and 103 were inhibitor-negative at the baseline. Among this latter group, 3 patients (2.9%) tested inhibitor-positive, with titers ranging from 1.2 to 2.1 BU/mL, with 4 patients below 1.0 BU/mL. One patient in the 11 PTPs investigated (PTP-I) developed antibodies against baby hamster kidney protein and mouse immunoglobulin G, but these findings were transient and asymptomatic. Hemostasis was achieved (markedly effective or effective) in 3666 of the 3855 bleeding episodes (95.1%) observed in 108 patients. Only 1 infusion was necessary in 3790 (98.3%) of these episodes. These data indicate that Kogenate is safe and very effective for the treatment of bleeding in PTPs with hemophilia A.
Key wordsHemophilia A Previously treated patients Tooth extraction Operation Recombinant factor VIII (Kogenate)
Unable to display preview. Download preview PDF.
- 4.Yoshioka A. Advances in hemophilia and other coagulation disorders: recombinant factor VIII preparations. Int J Pediatr Hematol Oncol. 1994;1:491–497.Google Scholar
- 6.Fukui H, Mori K, Ishikawa M, et al. A long-term, multicenter clinical study of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A [in Japanese]. Nihon Yuketsu Gakkai Zasshi. 1991;37:593–604.Google Scholar
- 8.Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors [letter]. Thromb Diath Haemorrh. 1975;34:869–872.Google Scholar
- 13.deBiasi R, Rocino A, Papa ML, et al. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost. 1994;71:544–547.Google Scholar
- 16.Lusher JM, Spira J, Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated B-domain deleted factor VIII (BDD rFVIII, rVIIISQ) in previously untreated severe hemophilia A patients. Thromb Haemost. 1999;82:1493.Google Scholar
- 17.Abe T, Igata A, Ikematsu S, et al. Multicenter clinical effect of heat-treated factor VIII (CP-8) preparation for patients with hemophilia A [in Japanese]. Rinshio to Kenkyu. 1985;62:3640–3659.Google Scholar
- 19.Fujimaki M, Goto M, Miyazaki T, et al. Clinical study of FVIII concentrate highly purified by monoclonal antibodies to FVIII(RCG- 11) [in Japanese]. Kiso to Rinsho. 1992;26:299–319.Google Scholar
- 27.Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost. 1998;79:872–875.CrossRefPubMedGoogle Scholar